Full Year 2024 Results Key Financial Results Revenue: US$33.4b (up 19% from FY 2023). Net ...
Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results